Biopharma stock Insmed (Nasdaq: INSM) doubles on Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis

Biopharma stock Insmed (Nasdaq: INSM) doubles on Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis: Biopharma stock Insmed (Nasdaq: INSM) doubles on Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis